Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Gabapentin to Tramadol in Children With Chronic Neuropathic or Mixed Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, aged 3 months to less than 18 years at screening.~2. Informed consent by parent(s) and/or legal guardian according to each country legal requirement.~3. Assent by the patient, where applicable, according to each country legal requirement.~4. Subjects that meet the diagnostic criteria for neuropathic or mixed pain.~5. Subjects that present with chronic pain defined as the recurrent or continuous pain persisting more than 3 months. Duration of pain will be determined from the date of the first pain experienced.~6. Subjects that present with at least moderate pain as defined by average pain intensity of ≥4/10 as assessed during a 3-day screening period~7. Stable underlying disease condition and treatment.~8. In presence of malignant diseases, subjects in clinical remission and/or no expected changes in their therapeutic protocol during participation to the present study.~Exclusion Criteria:~1. Pain duration of more than 5 years.~2. Current use of gabapentin or tramadol.~3. History of failure to respond to adequate treatment by gabapentin or tramadol/opioids for neuropathic pain.~4. History of epileptic condition except febrile seizure disorder.~5. Subjects with sleeping apnoea syndrome of any origin or subjects with history of severe respiratory impairment.~6. Subjects with diagnosis of sickle cell disease.~7. Subjects that present significant cognitive impairment.~8. Subjects that present current, controlled or uncontrolled, co-morbid psychiatric diagnosis that can impair pain diagnosis and assessment such as severe depressive conditions or psychosis.~9. Subjects with history of suicidal ideation or behaviour.~10. History of substance abuse in particular opioids.~11. Subjects under prohibited concomitant medication~12. Subjects in need for corticosteroid oral treatment or corticosteroid infiltrations to treat pain caused by infiltration or compression of neural structures, e.g. peripheral nerves or spinal cord.~13. Subjects born prematurely at ≤ 36 weeks gestational age, if recruited during the first year of age.~14. Subjects with a body mass index (BMI) for age and gender of \< 5th percentile or \> 95th percentile.~15. Subjects with glomerular filtration rate \< 90 mL/min/1.73 m2 (Schwarz equation).~16. Subjects with significant hepatic impairment or with Aspartate Transaminase (AST) or Alanine Transaminase (ALT) enzymes 3 times the upper limit of the age-specific reference range.~17. Subjects with known allergy, hypersensitivity or clinically significant intolerance to gabapentin or tramadol or any component found in the study drugs.~18. Subjects with fructose intolerance, diabetes, glucose-galactose malabsorption or lactase-isomaltase deficiency.~19. Subjects with clinically relevant abnormal ECG at the screening visit in the discretion of the Investigator/cardiologist.~20. Subjects participating in another clinical interventional trial.~21. Subjects scheduled for surgery or in recovery from surgery occurring within 3 months of baseline assessment.~22. Female subjects who are pregnant or currently lactating.~23. Subjects that failed screening or were previously enrolled in this study.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- gabapentin / placebo tramadol (Type: EXPERIMENTAL): gabapentin 75 mg/ml syrup / placebo tramadol, 3 times/day for 15 weeks.
- tramadol / placebo gabapentin (Type: ACTIVE_COMPARATOR): tramadol oral drops 100 mg/ml / placebo gabapentin, 3 times/day for 15 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).